1,721,059 research outputs found
Unresectable retroperitoneal malignant fibrous histiocytoma: Prolonged complete remission following chemoradiotherapy
No full textTwo cases of unresectable retroperitoneal malignant fibrous histiocytoma (MFH) achieving a prolonged complete remission by a combination of chemotherapy (adriamycin plus cyclophosphamide) and abdominal irradiation are reported. Although an optimal treatment policy for such cases has not been established, on the basis of data currently available, chemotherapy regimens including anthracyclines seem the most reliable therapeutic approach in unresectable and/or metastatic MFH
Comment on “Everolimus induces G1 cell cycle arrest through autophagy-mediated protein degradation of cyclin D1 in breast cancer cells”
No full textUpdating the role of radiotherapy in the management of epithelial ovarian cancer
No full textThe usefulness of radiotherapy in epithelial ovarian cancer (EOC) has been questioned in recent decades, on the grounds of the outstanding performances of modern drugs in terms of immediate therapeutic results. However, complete remission of the tumour after surgery and chemotherapy does not always turn into a definitive cure, and more than 50% of the patients have a poor ultimate prognosis. Radiotherapy can still play a role in this disease, whose complexity requires a multidisciplinary approach. Principles, techniques and results of radiation therapy are outlined here, with reference to authoritative experiences. The most significant issues of the last decade are reviewed, dealing with results of radiotherapy compared with those of chemotherapy in early stages (adjuvant setting), and with multidisciplinary approaches including both drug and radiation management in high-risk or advanced presentations. There is sound and wide evidence for the efficacy of radiation therapy in EOC. Radiotherapy is a reasonable alternative to chemotherapy in the adjuvant setting (complete removal of tumour at first surgery, moderate risk for recurrence on the basis of Stage II or III presentations or histologic grade 2 or 3), and can improve the results of chemotherapy after an "optimal" response to drugs, that is, absent or minimal tumour residuals detected by clinical or surgical-pathological re-staging. In this last case, whether or not the results of the prosecution of chemotherapy are better than those of consolidation radiotherapy has not been satisfactorily demonstrated. Aspects concerning toxicity are analysed, as well as possible improvements of the results of radiotherapy
Crosstalk between MicroRNA and Oxidative Stress in Physiology and Pathology
Full text linkMicroRNAs (miRNA), are short regulatory RNA molecules that regulate gene expression by binding specific sequences within target messenger RNA (mRNA) [...]
Emerging roles of microRNA in modulating cell-death processes in malignant glioma
No full textMicroRNAs (miRNAs) are small noncoding RNA molecules that regulate protein expression by cleaving or repressing the translation of target mRNAs. In mammals, their function mainly represses the mRNA transcripts via imperfect complementary sequences in the 3′UTR of target mRNAs. Several miRNAs have been recently reported to be involved in modulation of different genes in tumors, including glioblastoma, the most frequent brain tumor in adults. Despite the improvements in treatments, survival of patients remains poor, and glioblastoma is one of the most lethal form of human cancer. To define novel strategies against this tumor, emerging research investigated miRNAs involvement in glioblastoma. In particular, this review is focused on miRNAs involved on the two principal programmed cell-death, apoptosis and autophagy, recently described from the literature. Moreover, the discovery of miRNAs role in glioma cell-death pathways has also revealed a new category of therapeutic targets, fundamental for this kind of tumor
Clinical, Pathological, and Molecular Prognostic Parameters in Glioblastoma Patients Undergoing Chemo- and Radiotherapy
No full text- …
